Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H20N4O6 |
Molecular Weight | 376.3639 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)CO)C3=NC(=O)NC(=O)C3=N2
InChI
InChIKey=AUNGANRZJHBGPY-SCRDCRAPSA-N
InChI=1S/C17H20N4O6/c1-7-3-9-10(4-8(7)2)21(5-11(23)14(25)12(24)6-22)15-13(18-9)16(26)20-17(27)19-15/h3-4,11-12,14,22-25H,5-6H2,1-2H3,(H,20,26,27)/t11-,12+,14-/m0/s1
Molecular Formula | C17H20N4O6 |
Molecular Weight | 376.3639 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22406738
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22406738
Riboflavin (vitamin B2) is part of the vitamin B group. Riboflavin 5’-phosphate is the precursor of two coenzymes, flavin adenine dinucleotide and flavin mononucleotide, which catalyze oxidation/reduction reactions involved in a number of metabolic pathways. FAD and riboflavin phosphate in foods are hydrolyzed in the intestinal lumen by nucleotide diphosphatase and a variety of nonspecific phosphatases to yield free riboflavin, which is absorbed in the upper small intestines by a sodium-dependent saturable mechanism. Riboflavin has been used in several clinical and therapeutic situations. For over 30 years, riboflavin supplements have been used as part of the phototherapy treatment of neonatal jaundice. Corneal ectasia is a progressive thinning of the cornea; the most common form of this condition is keratoconus. Collagen cross-linking is a non-surgical treatment intended to slow progression of corneal ectasia by strengthening corneal tissue. The standard protocol calls for application directly to the eye of a 0.1% riboflavin solution for 30 minutes followed by 30 minutes of ultraviolet-A irradiation with a wavelength of 370 nm and power of 3 mW/cm2. Under the conditions used for corneal collagen cross-linking, riboflavin 5‘-phosphate functions as a photo enhancer and generates singlet oxygen which is responsible for the cross-linking.
Originator
Sources: Journal of Biological Chemistry (1928), 79, 733-8.iez8K9UZvDozY4ZRMmHj4&hl=ru&sa=X&ved=0ahUKEwiJ1reL0b_PAhWJVBQKHbdGBvEQ6AEIQjAF#v=onepage&q=Vitamin%20B2%20was%20discovered%20in%201920s&f=false
Curator's Comment: https://books.google.ru/books?id=b9ahvNjPFO8C&pg=PA63&lpg=PA63&dq=Vitamin+B2+was+discovered+in+1920s&source=bl&ots=KeZDSvz8CS&sig=gvCH_-
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PHOTREXA Approved UsePHOTREXA® VISCOUS and PHOTREXA® are indicated for use in corneal collagen cross-linking in combination with the KXL™ System for the treatment of 1.1 Progressive keratoconus 1.2 Corneal ectasia following refractive surgery. Launch Date1.46854078E12 |
|||
Primary | PHOTREXA Approved UsePHOTREXA® VISCOUS and PHOTREXA® are indicated for use in corneal collagen cross-linking in combination with the KXL™ System for the treatment of 1.1 Progressive keratoconus 1.2 Corneal ectasia following refractive surgery. Launch Date1.4684544E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
217.72 nM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8604671 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
674.2 nM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8604671 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
66 min |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIBOFLAVIN unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
In vivo expression of the collagen-related heat shock protein HSP47, following hyperthermia or photodynamic therapy. | 2001 |
|
Extracting biological information from DNA arrays: an unexpected link between arginine and methionine metabolism in Bacillus subtilis. | 2001 |
|
[Effects of biologically active supplements on the antioxidant and vitamin status of patients with hypertension and ischemic heart disease]. | 2001 |
|
The stressed synovium. | 2001 |
|
The enhancement of riboflavin-mediated photo-oxidation of doxorubicin by histidine and urocanic acid. | 2001 Apr |
|
Possible cause of G-C-->C-G transversion mutation by guanine oxidation product, imidazolone. | 2001 Apr |
|
Modeling and experimental design for metabolic flux analysis of lysine-producing Corynebacteria by mass spectrometry. | 2001 Apr |
|
Site-specific DNA damage at the GGG sequence by UVA involves acceleration of telomere shortening. | 2001 Apr 17 |
|
Biosynthesis of riboflavin. The reaction catalyzed by 6,7-dimethyl-8-ribityllumazine synthase can proceed without enzymatic catalysis under physiological conditions. | 2001 Apr 20 |
|
Photosensitizer initiated attacks on DNA under dry conditions and their inhibition: a DNA archiving issue. | 2001 Aug 15 |
|
Longitudinal vitamin and homocysteine levels in normal pregnancy. | 2001 Jan |
|
Crystal structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase of riboflavin biosynthesis. | 2001 Jan 10 |
|
Marginal vitamin and mineral intake of Costa Rican adolescents. | 2001 Jan-Feb |
|
Nutritional composition of uncommon foods and their role in meeting micronutrient needs. | 2001 Jul |
|
Long-term nutrient intake and early age-related nuclear lens opacities. | 2001 Jul |
|
Use of vitamin supplements and cataract: the Blue Mountains Eye Study. | 2001 Jul |
|
Riboflavin uptake in human trophoblast-derived BeWo cell monolayers: cellular translocation and regulatory mechanisms. | 2001 Jul |
|
The effects of thyroxine isomers on free-radical oxidation processes in subcellular fractions of rat cerebral cortex. | 2001 Jul-Aug |
|
Vitamin B intake and status in healthy Havanan men, 2 years after the Cuban neuropathy epidemic. | 2001 Jun |
|
[Energy and nutrient intake in compulsory high school students]. | 2001 Jun |
|
B vitamins induce an antinociceptive effect in the acetic acid and formaldehyde models of nociception in mice. | 2001 Jun 15 |
|
Relationships between dietary intake and cognitive function level in Korean elderly people. | 2001 Mar |
|
Limiting light-induced lipid peroxidation and vitamin loss in infant parenteral nutrition by adding multivitamin preparations to Intralipid. | 2001 Mar |
|
Recurrent cleft lip and palate in siblings of a patient with malabsorption syndrome, probably caused by hypovitaminosis a associated with folic acid and vitamin B(2) deficiencies. | 2001 Mar |
|
[Effect of coenzyme Q10 in patients with kidney diseases]. | 2001 May 24 |
|
Mechanism of the fluorescent light induced suppression of Curly phenotype in Drosophila melanogaster. | 2001 Sep |
|
Crystallization and preliminary crystallographic analysis of the recombinant N-terminal domain of riboflavin synthase. | 2001 Sep |
|
Metabolic flux analysis with a comprehensive isotopomer model in Bacillus subtilis. | 2001 Sep |
|
A Plackett-Burnam screening design directs the efficient formulation of multicomponent DRV liposomes. | 2001 Sep |
|
Biosynthesis of the phosphodiester bond in coenzyme F(420) in the methanoarchaea. | 2001 Sep 11 |
Patents
Sample Use Guides
instill 1 drop topically on the eye every 2 minutes for 30 minutes. After 30 minutes, examine the eye under slit lamp for presence of a yellow
flare in the anterior chamber. If flare is not detected, instill 1 drop every 2 minutes for an additional 2 to 3 drops and recheck for yellow flare.
Once flare is observed, perform ultrasound pachymetry. If corneal
thickness is less than 400 microns, instill 2 drops every 5 to 10 seconds until the corneal thickness increases to at least 400 microns.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27463630
Corneal stromal cells were covered with collagen (200 µL or 500 µL) and 0.1% riboflavin, and then exposed to ultraviolet light at 370 nm for 30 minutes
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:06:49 UTC 2023
by
admin
on
Fri Dec 15 15:06:49 UTC 2023
|
Record UNII |
TLM2976OFR
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QA11HA04
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
LIVERTOX |
NBK548710
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
WHO-ATC |
A11HA04
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
JECFA EVALUATION |
INS-101(III)
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
LOINC |
6695-1
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
DSLD |
2543 (Number of products:6659)
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
LOINC |
27099-1
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
27
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
LOINC |
49038-3
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
NCI_THESAURUS |
C45812
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
FDA ORPHAN DRUG |
352511
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
FDA ORPHAN DRUG |
344911
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
LOINC |
18374-9
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
LOINC |
2924-9
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
DSLD |
203 (Number of products:536)
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-101(I)
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
FDA ORPHAN DRUG |
468414
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
WHO-ATC |
S01XA26
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
CFR |
21 CFR 184.1695
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-101(III)
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
||
|
LOINC |
73723-9
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
817
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
493570
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
17015
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
INS-101(I)
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
RIBOFLAVIN
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | Description: A yellow to orange-yellow, crystalline powder; odourless or almost odourless. Solubility: Very slightly soluble in water; practically insoluble in ethanol (~750 g/l) TS, ether R, and acetone R. Category: Vitamin. Storage: Riboflavin should be kept in a tightly closed container, protected from light. Additional information: Riboflavin has a bitter taste. Solutions of Riboflavin, especially in dilute solutions of alkalis, deterioraterapidly when exposed to light. Definition: Riboflavin contains not less than 98.0% and not more than 102.0% of C17H20N4O6, calculated with reference to the dried substance. | ||
|
100000089010
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
DTXSID8021777
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
33298
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
176838
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
TLM2976OFR
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
C808
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
1603006
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
Riboflavin
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
201-507-1
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
D012256
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
CHEMBL1534
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
SUB10298MIG
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
419
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
RIBOFLAVIN
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
TLM2976OFR
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
m9595
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | Merck Index | ||
|
2834
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
83-88-5
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
57986
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | |||
|
9346
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY | RxNorm | ||
|
DB00140
Created by
admin on Fri Dec 15 15:06:49 UTC 2023 , Edited by admin on Fri Dec 15 15:06:49 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
correction factors: for the calculation of content, multiply the peak areas of the following impurity by the corresponding correction factor: impurity C = 2.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
correction factors: for the calculation of content, multiply the peak areas of the following impurity by the corresponding correction factor: impurity B = 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
correction factors: for the calculation of content, multiply the peak areas of the following impurity by the corresponding correction factor: impurity A = 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
|
||
|
IMPURITY -> PARENT |
correction factors: for the calculation of content, multiply the peak areas of the following impurity by the corresponding correction factor: impurity D = 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|